Viridian Therapeutics, Inc. (NASDAQ:VRDN) is a biotechnology company focused on developing treatments for rare diseases. On November 6, 2025, RBC Capital set a price target of $45 for VRDN, significantly higher than its current price of $27.50. This suggests a potential price increase of about 63.64%, indicating strong confidence in the company's future performance.
Viridian is set for a promising year in 2026, emerging from a slow period with successful financing transactions. These transactions have positioned the company to reach profitability without further share dilution, a positive sign for investors. This financial stability is crucial as it allows the company to focus on its core activities without the need to raise additional capital.
The competitive landscape for Viridian is also changing. Roche's Enspryng (satralizumab) has shown disappointing phase 3 results in treating thyroid eye disease. This reduces competitive pressure on Viridian's veligrotug and VRDN-003, both part of the IL-6 antibody class. This development could enhance Viridian's market position in treating thyroid eye disease, potentially increasing its market share.
Currently, VRDN is priced at $27.50, reflecting a 12.61% increase or $3.08. The stock has fluctuated between $24.93 and $28.60 today, with $28.60 being its highest price over the past year. The lowest price in the past year was $9.90. Viridian's market capitalization stands at approximately $2.23 billion, with a trading volume of 4.86 million shares today.
